Association of Obesity and Incidence of Lung Cancer with Interleukin-1β Antagonism

Association of Obesity and Incidence of Lung Cancer with Interleukin-1β Antagonism

In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) clinical study, patients were treated with canakinumab, an antibody that blocks the inflammatory molecule called interleukin-1β. The patients treated with this antibody had fewer occurrences of lung cancer during follow-up and fewer deaths from all cancers combined. A nuanced relationship exists between obesity and lung cancer. Obesity has been associated with increased incidence and progression of lung cancer. In general, obesity induces a state of inflammation which may be the driver for lung cancer.Our goal is to discern the correlation between obesity, inflammation, and lung cancer. The data from the CANTOS trial will be useful to investigate the association of obesity and obesity-associated inflammatory markers with the incidence of lung cancer. As part of the CANTOS trial, data related to various measures of obesity, i.e., body mass index (BMI), waist circumference (WC), and visceral adiposity index (VAI) was collected. The VAI is a mathematical model that uses both anthropometric (BMI and WC) and functional (triglycerides and high-density lipoprotein cholesterol) simple parameters.We hypothesize that there is a greater effect of canakinumab on lung cancer incidence and mortality in subjects with increased obesity than in non-obese patients.

[{ "PostingID": 21045, "Title": "NOVARTIS-CACZ885M2301", "Description": "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)" }]